Spectral AI Inc.

Spectral AI, Inc. is a predictive artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications in burn patients. The company's core product is the DeepView System, a predictive diagnostic device that provides physicians with objective, immediate assessments of a wound's healing potential prior to treatment or surgical intervention. The DeepView System uses AI-driven algorithms to deliver data-driven wound assessments intended to improve patient outcomes and reduce healthcare costs. The company generates revenue primarily through U.S. government research and development contracts, including a significant Project BioShield contract with BARDA and contracts through the Medical Technology Enterprise Consortium (MTEC) with the Department of Defense. Having received FDA De Novo clearance in May 2026, Spectral AI is transitioning from a development-stage company to one pursuing commercial sales of the DeepView System in the United States and internationally, with label expansion studies underway in the United Kingdom to cover additional body areas. Updated Aug 12, 2026